167 related articles for article (PubMed ID: 32101174)
1. Successful Desensitization to Oxaliplatin After a Single Initial Dose of Omalizumab in a Patient With Elevated IgE Levels.
Penella J; Quan P; Carvallo A; Chopitea A; Sala P; García Del Barrio MA; Gastaminza G; Goikoetxea MJ
J Investig Allergol Clin Immunol; 2020; 30(4):293-295. PubMed ID: 32101174
[No Abstract] [Full Text] [Related]
2. Unexpected Anaphylaxis After Completing a Desensitization Protocol to Oxaliplatin: Successful Adjuvant Use of Omalizumab.
Prieto-García A; Noguerado B; Rojas P; Torrado I; Rodríguez-Fernández A; Tornero P
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):53-55. PubMed ID: 30785102
[No Abstract] [Full Text] [Related]
3. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.
Ojaimi S; Harnett PR; Fulcher DA
J Allergy Clin Immunol Pract; 2014; 2(1):105-6. PubMed ID: 24565780
[No Abstract] [Full Text] [Related]
4. Usefulness of Omalizumab in Rapid Drug Desensitization in Patients With Severe Anaphylaxis Induced by Carboplatin: Open Questions.
Sánchez-Morillas L; Casado Herráez A; Rubio-Perez M; Robledo Echarren T; González Gutiérrez ML; Cimarra M; Vázquez Cortés S; Cerecedo I; Fernández-Rivas M
J Investig Allergol Clin Immunol; 2020; 30(4):298-300. PubMed ID: 32101175
[No Abstract] [Full Text] [Related]
5. Anaphylaxis after Elosulfase A infusion: Omalizumab as coadjuvant for enzyme replacement therapy desensitization.
Arroabarren E; Aznal E; Anda M; Sanchez-Valverde F
Pediatr Allergy Immunol; 2019 Jun; 30(4):491-494. PubMed ID: 30817035
[No Abstract] [Full Text] [Related]
6. Oxaliplatin hypersensitivity complicated by thrombocytopenia during desensitization.
Tuttle KL; Stavrou E; Hong DIC; Connell NT; Wickner P
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):267-269. PubMed ID: 33971363
[No Abstract] [Full Text] [Related]
7. Nanoallergen platform for detection of platin drug allergies.
Deak PE; Kim B; Adnan A; Labella M; De Las Vecillas L; Castells M; Bilgicer B
J Allergy Clin Immunol; 2019 May; 143(5):1957-1960.e12. PubMed ID: 30682456
[TBL] [Abstract][Full Text] [Related]
8. Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization.
Alvarez-Cuesta E; Madrigal-Burgaleta R; Angel-Pereira D; Ureña-Tavera A; Zamora-Verduga M; Lopez-Gonzalez P; Berges-Gimeno MP
Allergy; 2015 Jul; 70(7):784-94. PubMed ID: 25832325
[TBL] [Abstract][Full Text] [Related]
9. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment.
Madrigal-Burgaleta R; Berges-Gimeno MP; Angel-Pereira D; Ferreiro-Monteagudo R; Guillen-Ponce C; Pueyo C; Gomez de Salazar E; Alvarez-Cuesta E
Allergy; 2013 Jul; 68(7):853-61. PubMed ID: 23647576
[TBL] [Abstract][Full Text] [Related]
10. Pilot Experience Using Drug Provocation Testing for the Study of Hypersensitivity to Chemotherapy and Biological Agents.
Martí-Garrido J; Vázquez-Revuelta P; Lleonart-Bellfill R; Molina-Mata K; Muñoz-Sánchez C; Madrigal-Burgaleta R
J Investig Allergol Clin Immunol; 2021 Apr; 31(2):166-168. PubMed ID: 32573462
[No Abstract] [Full Text] [Related]
11. Successful oxaliplatin desensitization protocol in a patient with colorectal metastatic cancer.
de Lira-Quezada CE; Villarreal-Gonzalez RV; Gonzalez-Diaz SN; Carrasco-Diaz LL
J Oncol Pharm Pract; 2021 Mar; 27(2):490-493. PubMed ID: 32635810
[TBL] [Abstract][Full Text] [Related]
12. Platinum Chemotherapy Hypersensitivity: Prevalence and Management.
Otani IM; Wong J; Banerji A
Immunol Allergy Clin North Am; 2017 Nov; 37(4):663-677. PubMed ID: 28965633
[TBL] [Abstract][Full Text] [Related]
13. Does Rapid Drug Desensitization to Chemotherapy Affect Survival Outcomes?
Berges-Gimeno MP; Carpio-Escalona LV; Longo-Muñoz F; Bernal-Rubio L; Lopez-Gonzalez P; Gehlhaar P; Pachon V; Ferreiro-Monteagudo R; Madrigal-Burgaleta R; Alvarez-Cuesta E
J Investig Allergol Clin Immunol; 2020; 30(4):254-263. PubMed ID: 31188129
[TBL] [Abstract][Full Text] [Related]
14. Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening.
Vyskocil J; Tucek S; Kiss I; Fedorova L; Nevrlka J; Zdrazilova-Dubska L
Int Immunopharmacol; 2019 Sep; 74():105728. PubMed ID: 31288153
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin: Detection and Management of Hypersensitivity Reactions.
Rogers BB; Cuddahy T; Briscella C; Ross N; Olszanski AJ; Denlinger CS
Clin J Oncol Nurs; 2019 Feb; 23(1):68-75. PubMed ID: 30682002
[TBL] [Abstract][Full Text] [Related]
16. Skin testing and desensitization outcomes among platinum-sensitive oncology patients.
Mawhirt SL; Fonacier LS; Calixte R; Davis-Lorton M; Aquino MR
Ann Allergy Asthma Immunol; 2018 Apr; 120(4):437-439. PubMed ID: 29625667
[No Abstract] [Full Text] [Related]
17. Hypersensitivity and idiosyncratic reactions to oxaliplatin.
Bhargava P; Gammon D; McCormick MJ
Cancer; 2004 Jan; 100(1):211-2. PubMed ID: 14692042
[No Abstract] [Full Text] [Related]
18. Successful desensitization to oxaliplatin.
Mis L; Fernando NH; Hurwitz HI; Morse MA
Ann Pharmacother; 2005 May; 39(5):966-9. PubMed ID: 15784807
[TBL] [Abstract][Full Text] [Related]
19. First case of allergy to nivolumab.
Sáenz de Santa María García M; Noguerado-Mellado B; Rojas-Pérez-Ezquerra P; Prieto-García A; Bartolomé-Zavala B; Tornero P
J Allergy Clin Immunol Pract; 2017; 5(4):1140-1141. PubMed ID: 28284782
[No Abstract] [Full Text] [Related]
20. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
